Enovis Co. (NYSE:ENOV) Shares Acquired by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. increased its position in shares of Enovis Co. (NYSE:ENOV) by 54.5% in the 4th quarter, Holdings Channel reports. The firm owned 850 shares of the company’s stock after purchasing an additional 300 shares during the period. Pinnacle Bancorp Inc.’s holdings in Enovis were worth $37,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ENOV. Benjamin F. Edwards & Company Inc. boosted its stake in Enovis by 28.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after purchasing an additional 371 shares during the last quarter. Aigen Investment Management LP boosted its position in Enovis by 5.1% during the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock worth $381,000 after acquiring an additional 430 shares during the last quarter. FMR LLC grew its stake in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Enovis by 20.8% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company’s stock valued at $279,000 after acquiring an additional 1,115 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new position in Enovis in the 3rd quarter worth approximately $55,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Evercore ISI dropped their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a research report on Tuesday, October 1st. JMP Securities began coverage on Enovis in a report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $67.00.

Enovis Trading Down 0.5 %

Shares of Enovis stock opened at $45.50 on Friday. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -20.78 and a beta of 1.94. The stock has a 50 day moving average of $45.84 and a 200 day moving average of $44.34.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. During the same period last year, the company earned $0.56 EPS. The company’s quarterly revenue was up 21.0% on a year-over-year basis. As a group, research analysts predict that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.